Israel Elections NORTHERN SHIELD Gaza News BDS Antisemitism OMG Health & Science BUSINESS & TECH Premium Shapers of Israel Travel Channel

Teva

  • The Teva Pharmaceutical Industries

    Teva doubles down on Mylan, despite rejection

    Mylan rejected Teva's $41 billion bid earlier this week.

  • Teva

    Teva proposes $40 billion acquisition of competitor Mylan

    Acquisition would create leading company with potential to transform global market for generics.

  • Inside Teva

    US top court denies Israel's Teva Pharmaceuticals stay in Copaxone patent fight

    Teva sought stay of lower court ruling that favored developers of generic versions of its top selling multiple sclerosis drug.

  • Teva Pharmaceutical plant is seen in Jerusalem

    Teva pharmaceuticals to fire 5,000 worldwide, hundreds in Israel

    CEO of generics giant says move not due to financial distress; Teva employs 7500 people in Israel.

    By GALI WEINREB, SHAY NIV AND ADI BEN-ISRAEL / GLO

  • Teva Pharmaceutical plant is seen in Jerusalem

    Teva to pay heirs of employee fired cancer diagnosis

    Judge Ariella Gilzer-Kats: We were shown a dismal picture, which is inappropriate for a company in a civilized country.

    By CHEN MA'ANIT

  • Teva Pharmaceutical plant is seen in Jerusalem

    Yacimovich demands answers to Teva's low tax rate

    Labor chairwoman demands discussion in Knesset Finance Committee after Teva Pharmaceuticals reportedly paid a .3% tax rate.

    By NIV ELIS

  • Teva Pharmaceutical plant is seen in Jerusalem

    FDA denies Teva Copaxone generic trials petition

    Company hopes generic versions of MS drug will be delayed by clinical trials.

    By SHIRI HABIB-VALDHORN

  • Teva CEO JEREMY LEVIN

    2012 looks a banner year for Teva's Copaxone

    Expert: Company to report net profit of $4.74 billion this year.

    By NADAV NEUMAN

  • MK Moshe Gafni (UTJ)

    Knesset to debate tax hikes to rise by 1%

    If passed, VAT will rise one percentage point to 17%; Finance C'mtee reject Gafni proposal to raise corporate tax; Treasury General says "only a marginal increase."

    By NADAV SHEMER

  • Teva Pharmaceuticals

    Incoming Teva CEO reviews drug development

    Teva developing more than 70 innovative drugs

    By GLOBES CORRESPONDENT

  • The Jerusalem Post

    Commentary: Yanai bows to Teva investors’ pressure

    For a long time, market rumors have persisted that Yanai was on his way out.

    By SHIRI HABIB-VALDHORN/GLOBES

  • Teva Pharmaceutical plant is seen in Jerusalem

    Comment: A source of Anglo pride

    The appointment of Dr. Jeremy Levin to CEO of Teva Pharmaceuticals is the first time a foreigner has headed the company.

    By STEVE LINDE

  • Nation girds for general strike today in protest of Teva layoffs

    Morning flights halted at Ben-Gurion, public transit to operate as usual.

    By MAX SCHINDLER

    • Most Read
    Hot Opinion
    The Jerusalem Post Customer Service Center can be contacted with any questions or requests:    Telephone: *2421 * Extension 4 Jerusalem Post or 03-7619056 Fax: 03-5613699 E-mail: subs@jpost.com   The center is staffed and provides answers on Sundays through Thursdays between 07:00 and 14:00 and Fridays only handles distribution requests between 7:00 and  13:00   For international customers: The center is staffed and provides answers on Sundays through Thursdays between 7AM and 6PM  Toll Free number in Israel only 1-800-574-574  Telephone +972-3-761-9056 Fax: 972-3-561-3699 E-mail: subs@jpost.com
    Copyright © 2018 Jpost Inc. All rights reserved • Terms of Use • Privacy Policy
    ux design by: studio Inbar Edut
    •